MCID: CHR286
MIFTS: 38

Chronic Neutrophilic Leukemia

Categories: Blood diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Chronic Neutrophilic Leukemia

MalaCards integrated aliases for Chronic Neutrophilic Leukemia:

Name: Chronic Neutrophilic Leukemia 12 54 60 15 17 74
Leukemia Neutrophilic Chronic 56
Cnl 54

Characteristics:

Orphanet epidemiological data:

60
chronic neutrophilic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0080187
NCIt 51 C3179
MESH via Orphanet 46 D015467
ICD10 via Orphanet 35 D47.1
UMLS via Orphanet 75 C0023481
Orphanet 60 ORPHA86829
UMLS 74 C0023481

Summaries for Chronic Neutrophilic Leukemia

Disease Ontology : 12 A chronic leukemia characterized by neutrophilic leukocytosis with no detectable Philadelphia chromosome or BCR/ABL fusion gene.

MalaCards based summary : Chronic Neutrophilic Leukemia, also known as leukemia neutrophilic chronic, is related to chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. An important gene associated with Chronic Neutrophilic Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways is Hematopoietic cell lineage. The drugs Ketamine and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, bone and bone marrow, and related phenotype is Reduced mammosphere formation.

Wikipedia : 77 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent... more...

Related Diseases for Chronic Neutrophilic Leukemia

Diseases related to Chronic Neutrophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
# Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 29.9 ASXL1 CSF3R SETBP1
2 atypical chronic myeloid leukemia 29.8 ASXL1 CSF3R SETBP1
3 severe congenital neutropenia 29.5 CSF3 CSF3R
4 myelofibrosis 28.4 ASXL1 CALR CSF3 SRSF2
5 myelodysplastic syndrome 28.1 ASXL1 CSF3 CSF3R KMT2A SETBP1 SRSF2
6 myeloproliferative neoplasm 11.2
7 leukemia 10.9
8 pdgfrb-associated chronic eosinophilic leukemia 10.2
9 polycythemia vera 10.1
10 polycythemia 10.1
11 myeloma, multiple 10.1
12 myeloid leukemia 10.1
13 pulmonary alveolar microlithiasis 10.1
14 blood group--swann system 10.1
15 salla disease 10.1
16 monoclonal gammopathy of uncertain significance 10.0
17 hematopoietic stem cell transplantation 9.9
18 neutropenia 9.9
19 hypertrichosis 9.9 ASXL1 KMT2A
20 primary polycythemia 9.8 ASXL1 CALR
21 myelodysplastic myeloproliferative cancer 9.8 ASXL1 CSF3R SETBP1
22 leukemia, chronic lymphocytic 2 9.8
23 factor viii deficiency 9.8
24 leukemia, chronic lymphocytic 9.8
25 hemophilia a 9.8
26 cerebral hemorrhage 9.8
27 lymphocytic leukemia 9.8
28 nephrotic syndrome 9.8
29 mucormycosis 9.8
30 amyloidosis 9.8
31 miliary tuberculosis 9.8
32 hemophilia 9.8
33 acquired hemophilia 9.8
34 acquired hemophilia a 9.8
35 leukemia, b-cell, chronic 9.8
36 nonalcoholic steatohepatitis 9.8
37 hematologic cancer 9.8 CSF3 CSF3R KMT2A
38 aplastic anemia 9.6 ASXL1 CSF3 CSF3R
39 leukemia, chronic myeloid 9.5 CSF3 CSF3R KMT2A SETBP1
40 bone marrow cancer 9.5 CALR CSF3 CSF3R KMT2A
41 chronic leukemia 9.3 ASXL1 CSF3R SETBP1 SRSF2
42 leukemia, acute myeloid 8.8 ASXL1 CSF3 CSF3R KMT2A SETBP1 SRSF2

Graphical network of the top 20 diseases related to Chronic Neutrophilic Leukemia:



Diseases related to Chronic Neutrophilic Leukemia

Symptoms & Phenotypes for Chronic Neutrophilic Leukemia

GenomeRNAi Phenotypes related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CALR CSF3 CSF3R KMT2A

Drugs & Therapeutics for Chronic Neutrophilic Leukemia

Drugs for Chronic Neutrophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 228)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
3
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Acyclovir Approved Phase 3 59277-89-3 2022
6
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
8
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
9
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
10
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
11
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
12
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
13
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
14
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
15
Calcium Approved, Nutraceutical Phase 3,Phase 1,Phase 2,Not Applicable 7440-70-2 271
16
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Excitatory Amino Acids Phase 3
20 Anesthetics Phase 3
21 Anesthetics, Dissociative Phase 3
22 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
23 Excitatory Amino Acid Antagonists Phase 3
24 Analgesics Phase 3,Not Applicable
25 Anesthetics, Intravenous Phase 3
26 Anesthetics, General Phase 3
27 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
28 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
31 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
36 Antitubercular Agents Phase 3,Phase 1,Phase 2,Not Applicable
37 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2
38 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
39 Calcium, Dietary Phase 3,Phase 1,Phase 2,Not Applicable
40 Ophthalmic Solutions Phase 3,Phase 1,Phase 2
41 Cyclosporins Phase 3,Phase 1,Phase 2,Not Applicable
42 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1,Not Applicable
43 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 Narcotics Phase 3,Not Applicable
45 Analgesics, Opioid Phase 3,Not Applicable
46 Adjuvants, Anesthesia Phase 3
47 Liver Extracts Phase 3,Phase 1
48 Cola Phase 3,Phase 1
49 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 valacyclovir Phase 3

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
3 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
4 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
7 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
10 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
11 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
12 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
14 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
15 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
16 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
17 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
18 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
19 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
20 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
21 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
22 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
23 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
24 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
25 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
26 Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer Completed NCT00134017 Phase 2 Busulfan;Cyclophosphamide
27 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
28 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
29 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
30 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
31 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
32 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
33 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
34 Bone Marrow Transplant in Treating Patients With Hematologic Cancers Completed NCT00005797 Phase 2 busulfan;Cyclophosphamide;VP-16
35 Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Completed NCT00005622 Phase 2 cyclophosphamide
36 Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Recruiting NCT02092324 Phase 2 Ruxolitinib Phosphate
37 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
38 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
39 Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders Active, not recruiting NCT00544115 Phase 2 busulfan;cyclophosphamide;cyclosporine;etoposide;fludarabine phosphate;melphalan;methotrexate;mycophenolate mofetil;sirolimus;tacrolimus
40 Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Terminated NCT01159067 Phase 2 deferasirox
41 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2 sirolimus;tacrolimus
42 Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease Terminated NCT00719849 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
43 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
44 Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer Terminated NCT00295880 Phase 1, Phase 2
45 Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer Terminated NCT00281879 Phase 2 busulfan;carmustine;cyclophosphamide;cyclosporine;cytarabine;etoposide;fludarabine phosphate;melphalan;methotrexate;methylprednisolone;mycophenolate mofetil;tacrolimus
46 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
47 Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer Withdrawn NCT00816413 Phase 1, Phase 2 cyclosporine;mycophenolate mofetil;pentostatin
48 Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Withdrawn NCT00301912 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
49 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
50 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Completed NCT01484015 Phase 1 cefepime hydrochloride

Search NIH Clinical Center for Chronic Neutrophilic Leukemia

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Chronic Neutrophilic Leukemia

Anatomical Context for Chronic Neutrophilic Leukemia

MalaCards organs/tissues related to Chronic Neutrophilic Leukemia:

42
Neutrophil, Bone, Bone Marrow, Myeloid, Liver, Eye, Kidney

Publications for Chronic Neutrophilic Leukemia

Articles related to Chronic Neutrophilic Leukemia:

(show top 50) (show all 140)
# Title Authors Year
1
Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia. ( 30630849 )
2019
2
Clonal evolution in a chronic neutrophilic leukemia patient. ( 31076019 )
2019
3
Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. ( 28762112 )
2018
4
Chronic neutrophilic leukemia: new science and new diagnostic criteria. ( 29440636 )
2018
5
CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. ( 29449543 )
2018
6
Chronic neutrophilic leukemia. ( 29473201 )
2018
7
Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. ( 29512199 )
2018
8
Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review. ( 29587671 )
2018
9
Chronic neutrophilic leukemia, an extremely rare cause of neutrophilia in childhood: Cure with hematopoietic stem cell transplantation. ( 29676020 )
2018
10
Chronic neutrophilic leukemia. ( 29686565 )
2018
11
Colony-stimulating Factor 3 Receptor Mutated Chronic Neutrophilic Leukemia: A Rare Case Report. ( 30473959 )
2018
12
Chronic Neutrophilic Leukemia: Current and Future Perspectives. ( 30581159 )
2018
13
Septic Shock Predisposed by an Underlying Chronic Neutrophilic Leukemia with an Atypical Presentation; A Case Report. ( 30687064 )
2018
14
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
15
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis. ( 28158286 )
2017
16
Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia. ( 28209919 )
2017
17
Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. ( 27789332 )
2017
18
Genomics of chronic neutrophilic leukemia. ( 28028025 )
2017
19
Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. ( 28209656 )
2017
20
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. ( 28302714 )
2017
21
Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management. ( 26700908 )
2016
22
A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications. ( 26875968 )
2016
23
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. ( 27068405 )
2016
24
Chronic neutrophilic leukemia in a child with a CSF3R T618I germ line mutation. ( 27581359 )
2016
25
Dao K-HT, Tyner JW. What's different about atypical CML and chronic neutrophilic leukemia? Hematology Am Soc Hematol Educ Program. 2015;2015:264-271. ( 27913552 )
2016
26
Splenic rupture in primary amyloidosis with chronic neutrophilic leukemia. ( 25830123 )
2015
27
T618I-Mutated Colony Stimulating Factor 3 Receptor in Chronic Neutrophilic Leukemia and Chronic Myelomonocytic Leukemia Patients who Underwent Allogeneic Stem Cell Transplantation. ( 25932451 )
2015
28
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. ( 25480691 )
2015
29
Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice. ( 25575036 )
2015
30
Sweet's syndrome associated with chronic neutrophilic leukemia. ( 25751350 )
2015
31
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. ( 25850813 )
2015
32
A case of chronic neutrophilic leukemia successfully treated with pegylated interferon alpha-2a. ( 25983565 )
2015
33
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review. ( 26137042 )
2015
34
Chronic neutrophilic leukemia: a clinical perspective. ( 26366092 )
2015
35
Chronic neutrophilic leukemia with overexpression of EVI-1, and concurrent CSF3R and SETBP1 mutations: A case report. ( 26622734 )
2015
36
What's different about atypical CML and chronic neutrophilic leukemia? ( 26637732 )
2015
37
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
38
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
39
Treatment of coexisting chronic neutrophilic leukemia and light chain multiple myeloma with hydroxyurea, bortezomib, and dexamethasone. ( 25143840 )
2014
40
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. ( 25316523 )
2014
41
Chronic neutrophilic leukemia: a rare case report. ( 25332542 )
2014
42
Nephrotic syndrome related to chronic neutrophilic leukemia. ( 25366011 )
2014
43
Current strategies in the diagnosis and management of chronic neutrophilic leukemia. ( 25533830 )
2014
44
Chronic neutrophilic leukemia with plasma cell dyscrasia: friends or relatives? ( 23656197 )
2014
45
Plasma cell neoplasm associated chronic neutrophilic leukemia with membrane proximal and truncating CSF3R mutations. ( 24033109 )
2014
46
CALR mutation studies in chronic neutrophilic leukemia. ( 24421250 )
2014
47
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. ( 24445868 )
2014
48
Chronic Neutrophilic Leukemia with V617F JAK2 Mutation. ( 24839370 )
2014
49
Chronic neutrophilic leukemia 2014: Update on diagnosis, molecular genetics, and management. ( 24845374 )
2014
50
Pregnancy in a woman with chronic neutrophilic leukemia. ( 23344408 )
2013

Variations for Chronic Neutrophilic Leukemia

Expression for Chronic Neutrophilic Leukemia

Search GEO for disease gene expression data for Chronic Neutrophilic Leukemia.

Pathways for Chronic Neutrophilic Leukemia

Pathways related to Chronic Neutrophilic Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.61 CSF3 CSF3R

GO Terms for Chronic Neutrophilic Leukemia

Sources for Chronic Neutrophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....